Fractyl Health (NASDAQ:GUTS) CEO Buys $18,250.00 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan purchased 25,000 shares of the stock in a transaction on Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, with a total value of $18,250.00. Following the completion of the acquisition, the chief executive officer directly owned 540,557 shares of the company’s stock, valued at approximately $394,606.61. This represents a 4.85% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Fractyl Health Trading Down 1.1%

Shares of Fractyl Health stock traded down $0.01 during trading hours on Thursday, hitting $0.72. The company’s stock had a trading volume of 604,328 shares, compared to its average volume of 3,974,317. Fractyl Health, Inc. has a 12 month low of $0.38 and a 12 month high of $2.45. The stock has a 50 day moving average of $0.68 and a 200 day moving average of $1.08. The company has a market capitalization of $114.85 million, a PE ratio of -0.56 and a beta of 2.34. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.23. Analysts predict that Fractyl Health, Inc. will post -0.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Fractyl Health currently has an average rating of “Hold” and a consensus target price of $5.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Pale Fire Capital SE grew its stake in Fractyl Health by 84.5% in the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after purchasing an additional 2,711,103 shares in the last quarter. Accredited Investors Inc. bought a new position in Fractyl Health in the first quarter valued at approximately $46,000. Virtu Financial LLC bought a new position in Fractyl Health in the fourth quarter valued at approximately $153,000. Susquehanna Portfolio Strategies LLC bought a new position in Fractyl Health in the fourth quarter valued at approximately $108,000. Finally, Quadrature Capital Ltd grew its stake in Fractyl Health by 2,047.1% in the fourth quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock valued at $640,000 after purchasing an additional 277,174 shares in the last quarter.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.